311 related articles for article (PubMed ID: 20486731)
21. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union.
Smith MY; Attig B; McNamee L; Eagle T
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1168-73. PubMed ID: 22794309
[TBL] [Abstract][Full Text] [Related]
22. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
23. Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.
Ma C; Ascoytia C; McCarrier KP; Martin M; Feagan BG; Jairath V
Dig Dis Sci; 2018 Oct; 63(10):2555-2563. PubMed ID: 29959726
[TBL] [Abstract][Full Text] [Related]
24. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection.
Campbell S; Ghosh S
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):191-2. PubMed ID: 11246620
[TBL] [Abstract][Full Text] [Related]
25. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
de Ridder L; Escher JC; Taminiau JA
Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595
[TBL] [Abstract][Full Text] [Related]
26. Use of Anti-TNFα Agents and Time to First-time Surgery in Paediatric Patients with Ulcerative Colitis and Crohn's Disease.
Larsen MD; Qvist N; Nielsen J; Kjeldsen J; Nielsen RG; Nørgård BM
J Crohns Colitis; 2016 Jun; 10(6):650-6. PubMed ID: 26802081
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
[TBL] [Abstract][Full Text] [Related]
28. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease.
Kang B; Choi SY; Choi YO; Lee SY; Baek SY; Sohn I; Choe BH; Lee HJ; Choe YH
J Crohns Colitis; 2019 Feb; 13(2):189-197. PubMed ID: 30452616
[TBL] [Abstract][Full Text] [Related]
29. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
30. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
31. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
32. Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.
Baji P; Gulácsi L; Lovász BD; Golovics PA; Brodszky V; Péntek M; Rencz F; Lakatos PL
Scand J Gastroenterol; 2016 Jan; 51(1):22-7. PubMed ID: 26059967
[TBL] [Abstract][Full Text] [Related]
33. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
[TBL] [Abstract][Full Text] [Related]
34. Infliximab (Remicade): the magic bullet for Crohn's disease?
D'Haens G
Dig Liver Dis; 2000 Nov; 32(8):653-6. PubMed ID: 11142571
[No Abstract] [Full Text] [Related]
35. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
36. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.
Panaccione R;
Can J Gastroenterol; 2001 Jun; 15(6):371-5. PubMed ID: 11429666
[TBL] [Abstract][Full Text] [Related]
37. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
Gisbert JP; Panés J
Am J Gastroenterol; 2009 Mar; 104(3):760-7. PubMed ID: 19174781
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of Crohn's disease by infliximab. About 20 cases].
Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
[TBL] [Abstract][Full Text] [Related]
39. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group.
Mortimore M; Gibson PR; Selby WS; Radford-Smith GL; Florin TH;
Intern Med J; 2001 Apr; 31(3):146-50. PubMed ID: 11478343
[TBL] [Abstract][Full Text] [Related]
40. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
